Yeah, I am impressed with Michael powering through so much information in such a short time.
The host looked impressed with the information also even though you could tell he was not entirely knowledgeable on the subjects, that is the only thing holding us back it seems.
If investors can't see this huge opportunity staring back at them because they don't fully understand chemistry/biology, some of the posts last week led me to switch off Hotcopper as it was too infuriating that people are dismissing the MDXX potential because they have no basic understanding of chemistry.
We are literally looking at 140 variations that alter aspects of the drug, even completely removing the 'high' to treat dyskinesia which affects 40% of Parkinson’s Disease suffers after 4 years of treatment but yet we get posts like this, 66217434 "Why jump on the bandwagon of MDMA if the MDMA-LIKE was so amazing? Has the TGA rendered MDMA-LIKE useless now?"
It's an absolute slap in the face for the hard work the team has achieved.
A post from someone who suffers from PTSD, to say the company aiming to gain some revenue in the very near future is a negative, so they sell for profit with full intentions of buying back later, while the company is going to assist with multiple aspects of treatment then collect the data and use it to leverage a potential more suitable variation within MDXX for said treatment.
As I said in the past all this information has been out there for a while but traders are going to trade and I welcome their flip flopping position with conflicting and hypocritical buy/sell/hold recommendations but I am hoping the traders get left behind.
Sorry for the rant, I feel it just had to be said.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)